

Product Data Sheet

Product Name: SIRT2-IN-9

Cat. No.: GC66026

Chemical Properties

Cas. No. 522650-91-5


Formula $C_{21}H_{22}N_6OS_2$ M.Wt 438.57

Solubility DMSO : 4.46 mg/mL (10.17 mM; ultrasonic and warming and heat to 70°C) Storage 4°C, protect from light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

SIRT2-IN-9 (compound 12) is a selective inhibitor of **SRIT2** with an **IC₅₀** value of 1.3 μ M. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer^[1].

SIRT2-IN-9 (1-100 μ M; 15 min) dose-dependently inhibits SRIT2 with an IC₅₀ value of 1.3 μ M, and

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

inhibits SIRT1 and SIRT3 with IC_{50} s $\approx 300 \mu M$ ^[1].

SIRT2-IN-9 (0-50 μM ; 72 h) affects cell viability of MCF-7 cells^[1].

SIRT2-IN-9 (0-50 μM ; 6 h) affects acetylation of α -tubulin protein^[1].

Cell Proliferation Assay^[1]

Cell Line: MCF-7 breast cancer cell line

Concentration: 0-50 μM

Incubation Time: 72 hours

Result: Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells.

Western Blot Analysis^[1]

Cell Line: MCF-7 breast cancer cell line

Concentration: 6.25, 12.5, 25 and 50 μM

Incubation Time: 6 hours

Result: Dose-dependently increased acetylation of α -tubulin protein.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA